1. Home
  2. RPRX

as 08-29-2025 3:34pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Founded: 1996 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 15.6B IPO Year: 2020
Target Price: $45.33 AVG Volume (30 days): 3.1M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
2.45%
Dividend Payout Frequency: Quarterly
EPS: 2.32 EPS Growth: 54.86
52 Week Low/High: $24.05 - $38.00 Next Earning Date: 08-06-2025
Revenue: $2,305,243,000 Revenue Growth: 3.02%
Revenue Growth (this year): 33.77% Revenue Growth (next year): 4.62%

RPRX Daily Stock ML Predictions

Stock Insider Trading Activity of Royalty Pharma plc (RPRX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Norden Gregory RPRX N/A Aug 11 '25 Sell $36.23 33,500 $1,213,748.55 194,848

Share on Social Networks: